Pediatric Hematology/Oncology and Immunopathology

Вопросы гематологии/онкологии и иммунопатологии в педиатрии

1726-17082414-9314

Fund Doctors, Innovations, Science for Children

835

10.24287/1726-1708-2024-23-2-182-191

LITERATURE REVIEW

ОБЗОР ЛИТЕРАТУРЫ

Extracorporeal photopheresis for the treatment of graft-versus-host disease after hematopoietic stem cell transplantation

Экстракорпоральный фотоферез для лечения реакции «трансплантат против хозяина» после трансплантации гемопоэтических стволовых клеток

https://orcid.org/0000-0002-9881-1041

Kumukova

I. B.

Кумукова

И. Б.

Russian Federation

Irina B. Kumukova, Cand. Med. Sci., a researcher at the Department of Treatment and Prophylaxis Optimization for HSCT complications of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology; Head of the Department of Transfusion Medicine, a transfusion medicine physician at Kommunarka Moscow Multidisciplinary Clinical Center of the Department of Health of Moscow

1 Samory Mashela St., Moscow 117997

Кумукова Ирина Борисовна, канд. мед. наук, научный сотрудник отдела оптимизации лечения и профилактики осложнений трансплантации гемопоэтических стволовых клеток ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России; заведующая трансфузиологическим отделением – врач-трансфузиолог ГБУЗ «ММКЦ “Коммунарка” ДЗМ»

117997, Москва, ул. Саморы Машела, 1

irina_kumukova@mail.ru

https://orcid.org/0000-0003-4767-5382

Kurnikova

E. E.

Курникова

Е. Е.

Russian Federation

Moscow

Москва

ekurnikova@yandex.ru

https://orcid.org/0000-0002-0231-1617

Trakhtman

P. E.

Трахтман

П. Е.

Russian Federation

Moscow

Москва

trakhtman@mail.ru

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian FederationФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России

Kommunarka Moscow Multidisciplinary Clinical Center of the Department of Health of MoscowГБУЗ г. Москвы «Московский многопрофильный клинический центр “Коммунарка” Департамента здравоохранения г. Москвы»

08072024

232

1821910204202408042024

2025

«D. Rogachev NMRCPHOI»

ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России

https://creativecommons.org/licenses/by/4.0

https://hemoncim.com/jour/article/view/835

Graft-versus-host disease (GVHD) is one of the main complications of allogeneic hematopoietic stem cell transplantation. A large number of patients do not respond to corticosteroid therapy and require alternative treatment options. Extracorporeal photopheresis (ECP) is an empirically developed cell therapy that has proven effective in the treatment of both acute and chronic GVHD. Because ECP is safe to use and has few serious side effects, its application in the management of GVHD is very attractive. The purpose of this paper is to present a literature review on the use of ECP for the treatment of GVHD.

Реакция «трансплантат против хозяина» (РТПХ) является одним из основных осложнений аллогенной трансплантации гемопоэтических стволовых клеток. Значительная часть пациентов не отвечают на терапию глюкокортикостероидами и нуждаются в альтернативных методах лечения. Экстракорпоральный фотоферез (ЭКФ) является эмпирически разработанным методом клеточной терапии, который продемонстрировал свою эффективность в лечении как острой, так и хронической РТПХ. Поскольку ЭКФ безопасен в применении и имеет мало существенных побочных эффектов, его использование в лечении РТПХ является крайне привлекательным. Целью настоящего обзора является представление литературных данных о применении ЭКФ для лечения РТПХ.

extracorporeal photopheresisgraft-versus-host disease

экстракорпоральный фотоферезреакция «трансплантат против хозяина»

Greinix HT, Eikema DJ, Koster L et al. Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: An EBMT mega-file study. Haematologica (2022) 107(5):1054-63. https://doi.org/10.3324/haematol.2020.265769.

Zeiser R, Blazar BR. Pathophysiology of chronic graft-versus-Host disease and therapeutic targets. N Engl J Med (2017) 377(26):2565-79. https://doi.org/10.1056/NEJMra1703472.

Zeiser R, Blazar BR. Pathophysiology of chronic graft-versus-Host disease and therapeutic targets. N Engl J Med (2017) 377(26):2565–79. doi: 10.1056/NEJMra1703472.

Zeiser R, Blazar BR. Acute graft-versus-host disease - biologic process, prevention, and therapy. N Eng J Med. (2017) 377:2167-79. 10.1056/NEJMra1609337.

Zeiser R, Blazar BR. Acute graft-versus-host disease - biologic process, prevention, and therapy. N Eng J Med. (2017) 377:2167–79. 10.1056/NEJMra1609337.

Rashidi A, DeFor TE, Holtan SG et al. Outcomes and predictors of response in steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. (2019) 25:2297-302. 10.1016/j.bbmt.2019.07.017.

Martin PJ, Rizzo JD, Wingard JR, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Trans. (2012) 18:1150-63. 10.1016/j.bbmt.2012.04.005.

Pidala J, Kurland BF, Chai X et al.. Sensitivity of changes in chronic graft-versus-host disease activity to changes in patient-reported quality of life: results from the chronic graft-versus-Host disease consortium. Haematologica (2011) 96(10):1528-35. https://doi.org/10.3324/haematol.2011.046367

Flowers ME, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood (2002) 100(2):415-9. https://doi.org/10.1182/blood-2002-01-0011.

Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. Blood (2015) 125(4):606-15. https://doi.org/10.1182/blood-2014-08-551994.

Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. Blood (2015) 125(4):606–15. doi: 10.1182/blood-2014-08-551994.

Abu-Dalle I, Reljic T, Nishihori T, et al.. Extracorporeal photopheresis in steroid-refractory acute or chronic graft-versus-host disease: results of a systematic review of prospective studies. Biol Blood Marrow Transplant (2014) 20(11):1677-86. https://doi.org/10.1016/j.bbmt.2014.05.017.

10.

Flowers ME, Apperley JF, van Besien K, et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood (2008) 112(7):2667-74. https://doi.org/10.1182/blood-2008-03-141481.

11.

Malagola M, Cancelli V, Skert C, et al.. Extracorporeal photopheresis for treatment of acute and chronic graft versus host disease: An Italian multicentric retrospective analysis on 94 patients on behalf of the gruppo italiano trapianto di midollo osseo. Transplantation (2016) 100(12):e147-e55. https://doi.org/10.1097/TP.0000000000001466.

12.

Sakellari I, Gavriilaki E, Batsis I, et al. Favorable impact of extracorporeal photopheresis in acute and chronic graft versus host disease: Prospective single-center study. J Clin Apher (2018) 33(6):654-60. https://doi.org/10.1002/jca.21660.

13.

Кумукова И.Б., Трахтман П.Е., Курникова Е.Е. Экстракорпоральный фотоферез: как, зачем и для кого? Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2023;22(2):159-165. https://doi.org/10.24287/1726-1708-2023-22-2-159-165.

14.

Edelson RL. Mechanistic insights into extracorporeal photochemotherapy: efficient induction of monocyte-to-dendritic cell maturation. Transfus Apheresis Sci. 2014;50:322-9.

Edelson RL. Mechanistic insights into extracorporeal photochemotherapy: efficient induction of monocyte-to-dendritic cell maturation. Transfus Apheresis Sci. 2014;50:322–9.

15.

Ventura A, Vassall A, Yurter A, et al. Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells. J Vis Exp. 2019 May 17;(147). https://doi.org/10.3791/59370. PMID: 31157760.

Ventura A, Vassall A, Yurter A, et al. Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells. J Vis Exp. 2019 May 17;(147). doi: 10.3791/59370. PMID: 31157760.

16.

Ventura A, Vassall A, Robinson E, et al. Extracorporeal Photochemotherapy Drives Monocyte-to-Dendritic Cell Maturation to Induce Anticancer Immunity. Cancer Res. 2018;78:4045-58.

Ventura A, Vassall A, Robinson E, et al. Extracorporeal Photochemotherapy Drives Monocyte-to-Dendritic Cell Maturation to Induce Anticancer Immunity. Cancer Res. 2018;78:4045–58.

17.

Durazzo TS, Tigelaar RE, Filler R, et al. Induction of monocyte-to-dendritic cell maturation by extracorporeal photochemotherapy: initiation via direct platelet signaling Transfus Apheresis Sci. 2014;50(3):370-8. 10.1016/j.transci.2013.11.008.

18.

Wei BM, Hanlon D, Khalil D, et al.. Extracorporeal Photochemotherapy: Mechanistic Insights Driving Recent Advances and Future Directions. Yale J Biol Med. 2020 Mar 27;93(1):145-159. PMID: 32226344; PMCID: PMC7087063.

19.

Hannani D, Gabert F, Laurin D, et al. Photochemotherapy induces the apoptosis of monocytes without impairing their function. Transplantation, 89 (2010), pp. 492-499.

20.

Berger C, Hoffmann K, Vasquez JG, et al. Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy. Blood. 2010;116:4838-47.

21.

Fearnley DB, Whyte LF, Carnoutsos SA, et al. Monitoring human blood dendritic cell numbers in normal individuals and in stem cell transplantation. Blood, 93 (1999), pp. 728-736.

22.

Laroche L, Edelson R, Perez M, et al. Antigen-specific tolerance induced by autoimmunization with photoinactivated syngeneic effector cells. Ann NY Acad Sci. 1991;636:113-123.

Laroche L, Edelson R, Perez M, et al. Antigen-specific tolerance induced by autoimmunization with photoinactivated syngeneic effector cells. Ann NY Acad Sci. 1991;636:113–123.

23.

Perez M, Lobo FM, Yamane Y, et al. Inhibition of antiskin allograft immunity induced by infusions with photoinactivated effector T lymphocytes (PET cells). Is in vivo cell transferrable? Ann N Y Acad Sci. 1991 Dec 30;636:95-112. https://doi.org/10.1111/j.1749-6632.1991.tb33441.x. PMID: 1793234.

Perez M, Lobo FM, Yamane Y, et al. Inhibition of antiskin allograft immunity induced by infusions with photoinactivated effector T lymphocytes (PET cells). Is in vivo cell transferrable? Ann N Y Acad Sci. 1991 Dec 30;636:95-112. doi: 10.1111/j.1749-6632.1991.tb33441.x. PMID: 1793234.

24.

Schoenberger SP, Toes RE, van der Voort EI, et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393:480-483.

Schoenberger SP, Toes RE, van der Voort EI, et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393:480–483.

25.

Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science. 2003;300:339-342.

Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science. 2003;300:339–342.

26.

Griffith TS, Kazama H, VanOosten RL, et al. Apoptotic cells induce tolerance by generating helpless CD8+ T cells that produce TRAIL. J Immunol. 2007;178:2679-2687.

Griffith TS, Kazama H, VanOosten RL, et al. Apoptotic cells induce tolerance by generating helpless CD8+ T cells that produce TRAIL. J Immunol. 2007;178:2679–2687.

27.

Janssen EM, Droin NM, Lemmens EE, et al. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature. 2005;434:88-93.

Janssen EM, Droin NM, Lemmens EE, et al. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature. 2005;434:88–93.

28.

Spisek R., Gasova Z., Bartunkova J. Maturation state of dendritic cells during the extracorporeal photopheresis and its relevance for the treatment of chronic graft-versus-host disease. Transfusion, 46 (2006), pp. 55-65.

29.

Girardi M, Berger C, Wilson L, et al. Transimmunization for cutaneous T cell lymphoma: a Phase I study. Leuk Lymphoma. 2006;47:1495-1503.

Girardi M, Berger C, Wilson L, et al. Transimmunization for cutaneous T cell lymphoma: a Phase I study. Leuk Lymphoma. 2006;47:1495–1503.

30.

Di Renzo M, Sbano P, De Aloe G, et al. Extracorporeal photopheresis affects co-stimulatory molecule expression and interleukin-10 production by dendritic cells in graft-versus-host disease patients. Clin Exp Immunol. 2008;151:407-413.

31.

Legitimo A, Consolini R, Failli A, et al. In vitro treatment of monocytes with 8-methoxypsolaren and ultraviolet A light induces dendritic cells with a tolerogenic phenotype. Clin Exp Immunol. 2007;148:564-572.

32.

Clayton AR, Prue RL, Harper L, et al. Dendritic cell uptake of human apoptotic and necrotic neutrophils inhibits CD40, CD80, and CD86 expression and reduces allogeneic T cell responses: relevance to systemic vasculitis. Arthritis Rheum. 2003;48:2362-2374.

33.

Fadok VA, Bratton DL, Henson PM. Phagocyte receptors for apoptotic cells: recognition, uptake, and consequences. J Clin Invest. 2001;108:957-962.

Fadok VA, Bratton DL, Henson PM. Phagocyte receptors for apoptotic cells: recognition, uptake, and consequences. J Clin Invest. 2001;108:957–962.

34.

Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T cells and immune tolerance. Cell. 2008;133:775-787.

Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T cells and immune tolerance. Cell. 2008;133:775–787.

35.

Soares MV, Azevedo RI, Ferreira IA, et al. Naive and stem cell memory T cell subset recovery reveals opposing reconstitution patterns in CD4 and CD8 T cells in chronic graft vs. host disease. Front Immunol (2019) 10:334. https://doi.org/10.3389/fimmu.2019.0033.

36.

Alho AC, Kim HT, Chammas MJ, et al. Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. Blood (2016) 127(5):646-57. https://doi.org/10.1182/blood-2015-10-672345.

37.

Zorn E, Kim HT, Lee SJ, et al.. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood (2005) 106(8):2903-11. https://doi.org/10.1182/blood-2005-03-1257.

Zorn E, Kim HT, Lee SJ, et al.. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood (2005) 106(8):2903–11. doi: 10.1182/blood-2005-03-1257.

38.

Zhai Z, Sun Z, Li Q, et al.. Correlation of the CD4+CD25high T-regulatory cells in recipients and their corresponding donors to acute GVHD. Transpl Int (2007) 20(5):440-6. https://doi.org/10.1111/j.1432-2277.2007.00462.x.

Zhai Z, Sun Z, Li Q, et al.. Correlation of the CD4+CD25high T-regulatory cells in recipients and their corresponding donors to acute GVHD. Transpl Int (2007) 20(5):440–6. doi: 10.1111/j.1432-2277.2007.00462.x.

39.

Kim S, Elkon KB, Ma X. Transcriptional suppression of interleukin-12 gene expression following phagocytosis of apoptotic cells. Immunity. 2004;21:643-653.].

Kim S, Elkon KB, Ma X. Transcriptional suppression of interleukin-12 gene expression following phagocytosis of apoptotic cells. Immunity. 2004;21:643–653.].

40.

Rubegni P, Sbano P, Cevenini G, et al. CD4+CD25+ lymphocyte subsets in chronic graft versus host disease patients undergoing extracorporeal photochemotherapy. Int J Immunopathol Pharmacol (2007) 20(4):801-7. https://doi.org/10.1177/039463200702000416.

41.

Biagi E, Di Biaso I, Leoni V, et al.. Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+CD62L+ functional regulatory T-cells in patients with graft-versus-host disease. Transplantation (2007) 84(1):31-9. https://doi.org/10.1097/01.tp.0000267785.52567.9c.

42.

Di Biaso I, Di Maio L, Bugarin C, et al. Regulatory T cells and extracorporeal photochemotherapy: correlation with clinical response and decreased frequency of proinflammatory T cells. Transplantation (2009) 87(9):1422-5. https://doi.org/10.1097/TP.0b013e3181a27a5d.

43.

Knobler R., Barr M.L., Couriel D.R., et al.Extracorporeal photopheresis: past, present, and future. J Am Acad Dermatol, 61 (2009), pp. 652-665.

44.

Nygaard M, Wichert S, Berlin G, et al. Extracorporeal photopheresis for graft-vs-host disease: A literature review and treatment guidelines proposed by the Nordic ECP quality group. Eur J Haematol (2020) 104(5):361-75. https://doi.org/10.1111/ejh.13381.

45.

Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019 Jun;34(3):171-354. https://doi.org/10.1002/jca.21705. PMID: 31180581.

46.

Greinix HT, Knobler RM, Worel N, et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica. 2006; 91(3): 405-408.

47.

Greinix HT, van Besien K, Elmaagacli AH, et al. Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis-results of a crossover randomized study. Biol Blood Marrow Transplant (2011) 17(12):1775-82. https://doi.org/10.1016/j.bbmt.2011.05.004.

Greinix HT, van Besien K, Elmaagacli AH, et al. Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis–results of a crossover randomized study. Biol Blood Marrow Transplant (2011) 17(12):1775–82. doi: 10.1016/j.bbmt.2011.05.004.

48.

Hackstein H, Amoros JJ, Bein G, et al. Successful use of miniphotopheresis for the treatment of graft-versus-host disease. Transfusion. 2014 Aug;54(8):2022-7. https://doi.org/10.1111/trf.12596. Epub 2014 Mar 25. PMID: 24666366.

Hackstein H, Amoros JJ, Bein G, et al. Successful use of miniphotopheresis for the treatment of graft-versus-host disease. Transfusion. 2014 Aug;54(8):2022-7. doi: 10.1111/trf.12596. Epub 2014 Mar 25. PMID: 24666366.

49.

Matic T, Bojanic I, Mazic S, et al. An automated mini buffy coat preparation method for use in mini extracorporeal photopheresis treatment of graft-vs-host-disease in a low body weight pediatric patient. J Clin Apher. 2019 Aug;34(4):468-473. https://doi.org/10.1002/jca.21700. Epub 2019 Mar 4. PMID: 30829417.

Matic T, Bojanic I, Mazic S, et al. An automated mini buffy coat preparation method for use in mini extracorporeal photopheresis treatment of graft-vs-host-disease in a low body weight pediatric patient. J Clin Apher. 2019 Aug;34(4):468-473. doi: 10.1002/jca.21700. Epub 2019 Mar 4. PMID: 30829417.

50.

[Kumukova I.B., Kurnikova E.E., Ilyushina M.A., Trakhtman P.E. Mini photopheresis – a non leukapheresis based extracorporeal photopheresis: clinical experience. Pediatrics. Journal named after G.N. Speransky 2021; 100 (3): 69–76. (In Russ.) DOI: 10.24110/0031-403X-2021-100-3-69-76

Кумукова И.Б., Курникова Е.Е., Илюшина М.А., Трахтман П.Е.. Мини-фотоферез – экстракорпоральный фотоферез, не требующий лейкафереза: опыт клинического использования. Педиатрия им. Г.Н. Сперанского. 2021; 100 (3): 69-76.

51.

Kumukova I, Kurnikova E, Trakhtman P. Extracorporeal photopheresis: Is one ounce of blood enough? Case reports. Pediatr Blood Cancer. 2024 Mar;71(3):e30800. https://doi.org/10.1002/pbc.30800. Epub 2023 Dec 17. PMID: 38105463.

Kumukova I, Kurnikova E, Trakhtman P. Extracorporeal photopheresis: Is one ounce of blood enough? Case reports. Pediatr Blood Cancer. 2024 Mar;71(3):e30800. doi: 10.1002/pbc.30800. Epub 2023 Dec 17. PMID: 38105463.

52.

Dunbar NM, Raval JS, Johnson A, et al. Extracorporeal photopheresis practice patterns: An international survey by the ASFA ECP subcommittee. J Clin Apher (2017) 32(4):215-23. https://doi.org/10.1002/jca.21486.

Dunbar NM, Raval JS, Johnson A, et al. Extracorporeal photopheresis practice patterns: An international survey by the ASFA ECP subcommittee. J Clin Apher (2017) 32(4):215–23. doi: 10.1002/jca.21486.

53.

Hambsch J, Büttner S, Heck M, et al. Unizentrische, retrospektive Analyse der praktischen Durchführung der extrakorporalen Photopherese : Periphervenöser und zentralvenöser Zugang im Vergleich [Single-center retrospective analysis of extracorporal photopheresis in clinical practice : Peripheral venous compared to central venous access]. Hautarzt. 2019 Mar;70(3):193-203. German. https://doi.org/10.1007/s00105-018-4327-y. PMID: 30627743.

54.

Adamski J. Vascular access considerations for extracorporeal photopheresis. Transfusion. 2018 Feb;58 Suppl 1:590-597. https://doi.org/10.1111/trf.14500. PMID: 29443405.

Adamski J. Vascular access considerations for extracorporeal photopheresis. Transfusion. 2018 Feb;58 Suppl 1:590-597. doi: 10.1111/trf.14500. PMID: 29443405.

55.

Schwede K, Nagel S, Simon JC, et al. How to perform extracorporeal photopheresis via port catheter. Transfusion. 2017 Nov;57(11):2567-2570. https://doi.org/10.1111/trf.14265. Epub 2017 Aug 7. PMID: 28782257.

Schwede K, Nagel S, Simon JC, et al. How to perform extracorporeal photopheresis via port catheter. Transfusion. 2017 Nov;57(11):2567-2570. doi: 10.1111/trf.14265. Epub 2017 Aug 7. PMID: 28782257.

56.

Candler KS, Anderson J, Edmiston W, et al. Retrospective, single center study of Smart PortTM CT implanted catheters (Vortex port) for post transplant extracorporeal photopheresis for treatment of steroid refractory graft-vs-host disease. Biol Blood Marrow Transplant 2011; 17: S346.

57.

Ryan MJ. Approval letter: PowerFlow™ implantable apheresis IV port. Silver Spring (MD): Food and Drug Administration; 2017 Apr 17 [cited 2017 Sep 21]. Доступно о ссылке: https://www.accessdata.fda.gov/cdrh_docs/pdf16/K163.

58.

Kaufman RM, Djulbegovic B, Gernsheimer T, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med (2015) 162(3):205-13. https://doi.org/10.7326/M14-1589.

Kaufman RM, Djulbegovic B, Gernsheimer T, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med (2015) 162(3):205–13. doi: 10.7326/M14-1589.

59.

Liu C, Shah K, Dynis M, et al. Linear relationship between lymphocyte counts in peripheral blood and buffy coat collected during extracorporeal photopheresis. Transfusion (2013) 53(11):2635-43. https://doi.org/10.1111/trf.12114.

60.

Pierelli L, Perseghin P, Marchetti M, et al. Extracorporeal photopheresis for the treatment of acute and chronic graft-versus-host disease in adults and children: best practice recommendations from an Italian society of hemapheresis and cell manipulation (SIdEM) and Italian group for bone marrow transplantation (GITMO) consensus process. Transfusion (2013) 53(10):2340-52. https://doi.org/10.1111/trf.12059.

61.

Faivre L, Lecouflet L, Liu WQ, et al. Quality control of extracorporeal photochemotherapy: Proliferation assay using CFSE validated according to ISO 15189:2007 standards. Cytometry B Clin Cytom (2015) 88(1):30-9. https://doi.org/10.1002/cytob.21188.

62.

Schwab L, Michel G, Bein G, et al. CD71 surface analysis of T cells: a simple alternative for extracorporeal photopheresis quality control. Vox Sang (2020) 115(1):81-93. https://doi.org/10.1111/vox.12850.

Schwab L, Michel G, Bein G, et al. CD71 surface analysis of T cells: a simple alternative for extracorporeal photopheresis quality control. Vox Sang (2020) 115(1):81–93. doi: 10.1111/vox.12850.

63.

Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. preliminary results. N Engl J Med (1987) 316(6):297-303. https://doi.org/10.1056/NEJM198702053160603. quality group. Eur J Haematol (2020) 104(5):361-75. https://doi.org/10.1111/ejh.13381.

Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. preliminary results. N Engl J Med (1987) 316(6):297–303. doi: 10.1056/NEJM198702053160603. quality group. Eur J Haematol (2020) 104(5):361–75. doi: 10.1111/ejh.13381.

64.

Golestaneh L, Mokrzycki MH. Vascular access in therapeutic apheresis: update 2013. J Clin Apher 2013; 28: 64-72.

65.

Bhutta ST, Culp WC. Evaluation and management of central venous access complications. Tech Vasc Interv Radiol 2011; 14: 217-24.

66.

Vieyra-Garcia PA, Wolf P. Extracorporeal photopheresis: A case of immunotherapy ahead of its time. Transfus Med Hemother (2020) 47(3):226-35. https://doi.org/10.1159/000508479.

Vieyra-Garcia PA, Wolf P. Extracorporeal photopheresis: A case of immunotherapy ahead of its time. Transfus Med Hemother (2020) 47(3):226–35. doi: 10.1159/000508479.

67.

Blaha M, Gasova Z, Berlin G, et al. Analysis of extracorporeal photopheresis within the frame of the WAA register. Transfus Apher Sci. 2021 Oct;60(5):103172. https://doi.org/10.1016/j.transci.2021.103172. Epub 2021 May 27. PMID: 34059472.

Blaha M, Gasova Z, Berlin G, et al. Analysis of extracorporeal photopheresis within the frame of the WAA register. Transfus Apher Sci. 2021 Oct;60(5):103172. doi: 10.1016/j.transci.2021.103172. Epub 2021 May 27. PMID: 34059472.

68.

Kanold J, Paillard C, Halle P, et al. Extracorporeal photochemotherapy for graft versus host disease in pediatric patients. Transfusion and Apheresis Science 2003;28(1):71‐80.

69.

Cho A, Paulitschke V, Knobler R. Mode of action, indications and recommendations on extracorporeal photopheresis (ECP). J Dtsch Dermatol Ges. 2023 Nov;21(11):1369-1380. https://doi.org/10.1111/ddg.15167. Epub 2023 Sep 18. PMID: 37723908.

Cho A, Paulitschke V, Knobler R. Mode of action, indications and recommendations on extracorporeal photopheresis (ECP). J Dtsch Dermatol Ges. 2023 Nov;21(11):1369-1380. doi: 10.1111/ddg.15167. Epub 2023 Sep 18. PMID: 37723908.

70.

Gandelman JS, Song DJ, Chen H, et al. A prospective trial of extracorporeal photopheresis for chronic graft-versus-Host disease reveals significant disease response and no association with frequency of regulatory T cells. Biol Blood Marrow Transplant (2018) 24(12):2373-80. https://doi.org/10.1016/j.bbmt.2018.06.035.

71.

Jagasia M, Greinix H, Robin M, et al.. Extracorporeal photopheresis versus anticytokine therapy as a second-line treatment for steroid-refractory acute GVHD: a multicenter comparative analysis. Biol Blood Marrow Transplant (2013) 19(7):1129-33. https://doi.org/10.1016/j.bbmt.2013.04.018.

72.

Das-Gupta E, Greinix H, Jacobs R, et al. Extracorporeal photopheresis as second-line treatment for acute graft-versus-host disease: impact on six-month freedom from treatment failure. Haematologica. 2014 Nov;99(11):1746-52. https://doi.org/10.3324/haematol.2014.108217. Epub 2014 Aug 22. PMID: 25150260; PMCID: PMC4222474.

Das-Gupta E, Greinix H, Jacobs R, et al. Extracorporeal photopheresis as second-line treatment for acute graft-versus-host disease: impact on six-month freedom from treatment failure. Haematologica. 2014 Nov;99(11):1746-52. doi: 10.3324/haematol.2014.108217. Epub 2014 Aug 22. PMID: 25150260; PMCID: PMC4222474.

73.

Worel N, Lehner E, Führer H, et al. Extracorporeal photopheresis as second-line therapy for patients with acute graft-versus-host disease: does the number of cells treated matter? Transfusion. 2018 Apr;58(4):1045-1053. https://doi.org/10.1111/trf.14506. Epub 2018 Feb 15. PMID: 29446444.

Worel N, Lehner E, Führer H, et al. Extracorporeal photopheresis as second-line therapy for patients with acute graft-versus-host disease: does the number of cells treated matter? Transfusion. 2018 Apr;58(4):1045-1053. doi: 10.1111/trf.14506. Epub 2018 Feb 15. PMID: 29446444.

74.

Garban F, Drillat P, Makowski C, et al. Extracorporeal chemophototherapy for the treatment of graft-versus-host disease: hematologic consequences of short-term, intensive courses. Haematologica. (2005) 90:1096-101.

75.

Perfetti P, Carlier P, Strada P, et al.. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. Bone Marrow Trans. (2008) 42:609-17. 10.1038/bmt.2008.221.

Perfetti P, Carlier P, Strada P, et al.. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. Bone Marrow Trans. (2008) 42:609–17. 10.1038/bmt.2008.221.

76.

Asensi Cantó P, Sanz Caballer J, Sopeña Pell-Ilderton C, et al. Real-World Experience in Extracorporeal Photopheresis for Adults with Graft-versus-Host Disease. Transplant Cell Ther. 2023 Dec;29(12):765.e1-765.e8. https://doi.org/10.1016/j.jtct.2023.09.001. Epub 2023 Sep 12. PMID: 37703997.

Asensi Cantó P, Sanz Caballer J, Sopeña Pell-Ilderton C, et al. Real-World Experience in Extracorporeal Photopheresis for Adults with Graft-versus-Host Disease. Transplant Cell Ther. 2023 Dec;29(12):765.e1-765.e8. doi: 10.1016/j.jtct.2023.09.001. Epub 2023 Sep 12. PMID: 37703997.

77.

Malagola M, Cancelli V, Skert C, et al. Extracorporeal Photopheresis for Treatment of Acute and Chronic Graft Versus Host Disease: An Italian Multicentric Retrospective Analysis on 94 Patients on Behalf of the Gruppo Italiano Trapianto di Midollo Osseo. Transplantation. 2016 Dec;100(12):e147-e155. https://doi.org/10.1097/TP.0000000000001466. PMID: 27861297.

78.

Foss FM, DiVenuti GM, Chin K, et al.. Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors. Bone Marrow Transplant (2005) 35(12):1187-93. https://doi.org/10.1038/sj.bmt.1704984.

79.

Jagasia M, Scheid C, Socié G, et al.. Randomized controlled study of ECP with methoxsalen as first-line treatment of patients with moderate to severe cGVHD. Blood Adv (2019) 3(14):2218-29. https://doi.org/10.1182/bloodadvances.2019000145.

80.

Malik MI, Litzow M, Hogan W, et al.. Extracorporeal photopheresis for chronic graft-versus-host disease: a systematic review and meta-analysis. Blood Res (2014) 49(2):100-6. https://doi.org/10.5045/br.2014.49.2.100.

Malik MI, Litzow M, Hogan W, et al.. Extracorporeal photopheresis for chronic graft-versus-host disease: a systematic review and meta-analysis. Blood Res (2014) 49(2):100–6. doi: 10.5045/br.2014.49.2.100.

81.

Alfred A, Taylor PC, Dignan F, et al. The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK photopheresis society. Br J Haematol (2017) 177(2):287-310. https://doi.org/10.1111/bjh.14537.

82.

Del Fante C, Scudeller L, Viarengo G, et al. Response and survival of patients with chronic graft-versus-host disease treated by extracorporeal photochemotherapy: a retrospective study according to classical and national institutes of health classifications. Transfusion (2012) 52(9):2007-15. https://doi.org/10.1111/j.1537-2995.2011.03542.x

83.

Maas-Bauer K, Kiote-Schmidt C, Bertz H, et al.. Ruxolitinib-ECP combination treatment for refractory severe chronic graft-versus-host disease. Bone Marrow Transplant (2021) 56(4):909-16. https://doi.org/10.1038/s41409-020-01122-8.

84.

Buder K, Zirngibl M, Bapistella S, et al. Extracorporeal photopheresis versus alternative treatment for chronic graft‐versus‐host disease after haematopoietic stem cell transplantation in children and adolescents. Cochrane Database of Systematic Reviews 2022, Issue 6. Art. No.: CD009898. https://doi.org/10.1002/14651858.CD009898.pub4.

85.

Dignan FL, Aguilar S, Scarisbrick JJ et al.. Impact of extracorporeal photopheresis on skin scores and quality of life in patients with steroid-refractory chronic GVHD. Bone Marrow Trans. (2014) 49:704-8. 10.1038/bmt.2014.21.

86.

Suchin KR, Cassin M, Washko R, et al.. Extracorporeal photochemotherapy does not suppress T- or b-cell responses to novel or recall antigens. J Am Acad Dermatol (1999) 41(6):980-6. https://doi.org/10.1016/S0190-9622(99)70257-4.